Global Endometriosis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Endometriosis Treatment Market is presumed to reach the market size of nearly USD 33.73 BN by 2030 from USD 5.44 BN in 2022 with a CAGR of 25.62% under the study period 2023 - 2030.

Endometriosis is a painful gynaecological disorder in which endometrial-like tissues start growing in other parts of the abdomen and pelvic areas. Some places where endometriosis can develop are the fallopian tubes, vagina, intestine, rectum, diaphragm, bladder and ureter, outside and back of the uterus etc. Its symptoms may include heavy pain during menstruation, cramps, pain during sex, heavy bleeding during periods, painful bowel movements, abdominal pain during periods and others. Pain medications and hormone therapy are used to reduce the symptoms of endometriosis. The surgical options for the treatment of endometriosis are laparoscopy as well as hysterectomy.

Market Dynamics:

The demand for the endometriosis treatment market is scaling up due to the rising number of cases and the growing need for treatment of endometriosis. Government initiative and awareness programs across several countries to create awareness regarding this disease among people is surging the demand for this market. Moreover, the rise in research and development activities associated with discovering better treatment options propels the demand for this market. Patient assistance programs for expensive drugs are augmenting the demand for this market. Furthermore, growing investment in healthcare sectors to provide better treatment facilities is boosting the growth of this market. Conversely, the unavailability of non-invasive diagnostic tests for endometriosis may obstruct the growth of the endometriosis treatment market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of endometriosis treatment. The growth and trends of endometriosis treatment industry provide a holistic approach to this study.

Market Segmentation:

This section of the endometriosis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Type

Pain Medication
Hormone Therapy

By Drug Class

NSAIDs
Oral Contraceptive
Gonadotropin Releasing Hormone
Others

By Route Of Administration

Oral
Injectable
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Endometriosis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the endometriosis treatment market include Bayer AG, Pfizer Inc., AbbVie Inc, AstraZeneca, ObsEva SA, Teva Pharmaceutical Industries, Zydus Healthcare Limited, Eli Lilly and Company, Astellas Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112110345

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ENDOMETRIOSIS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment Type
- 3.7.2 Market Attractiveness Analysis By Drug Class
- 3.7.3 Market Attractiveness Analysis By Route Of Administration
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

6.1 Overview by Treatment Type
6.2 Historical and Forecast Data
6.3 Analysis by Treatment Type
6.4 Pain Medication Historic and Forecast Sales by Regions
6.5 Hormone Therapy Historic and Forecast Sales by Regions

7 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY DRUG CLASS

7.1 Overview by Drug Class
7.2 Historical and Forecast Data
7.3 Analysis by Drug Class
7.4 NSAIDs Historic and Forecast Sales by Regions
7.5 Oral Contraceptive Historic and Forecast Sales by Regions
7.6 Gonadotropin Releasing Hormone Historic and Forecast Sales by Regions
7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

8.1 Overview by Route Of Administration
8.2 Historical and Forecast Data
8.3 Analysis by Route Of Administration
8.4 Oral Historic and Forecast Sales by Regions
8.5 Injectable Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

9.1 Overview by Distribution Channel
9.2 Historical and Forecast Data
9.3 Analysis by Distribution Channel
9.4 Hospital Pharmacy Historic and Forecast Sales by Regions
9.5 Retail Pharmacy Historic and Forecast Sales by Regions
9.6 Others Historic and Forecast Sales by Regions

10 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE ENDOMETRIOSIS TREATMENT COMPANIES

11.1. Endometriosis Treatment Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF ENDOMETRIOSIS TREATMENT INDUSTRY

12.1. Top Company Share Analysis
12.2. Market Concentration Rate
12.3. Bayer AG
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Pfizer Inc.
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. AbbVie Inc
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. AstraZeneca
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. ObsEva SA
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Teva Pharmaceutical Industries
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Zydus Healthcare Limited
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Eli Lilly and Company
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments
12.11. Astellas Pharma Inc.
- 12.11.1. Company Overview
- 12.11.2. Company Revenue
- 12.11.3. Products
- 12.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies